| Date | Title | Description |
| 11.07.2026 | Beeline Medicines Closes $426.3M Series A, Accelerates Autoimmune Drug Development | Beeline Medicines, a clinical-stage biotechnology firm in Stamford, CT, announced a significant Series A extension. It secured an additional $126.3 million. This pushed its total Series A funding to an impressive $426.3 million. The capital... |
| 08.07.2026 | Beeline Medicines Raises $426.3 Million Series A To Advance Autoimmune And Inflammatory Disease Portfolio | Beeline Medicines announced the closing of a $126.3 million Series A extension. The new funding brings the company’s total Series A financing round to $426.3 million. The extension adds to Beeline Medicines’ previously announced $300 millio... |
| 08.07.2026 | Venture Capital & Startup Funding Roundup, July 8, 2026 | It’s Wednesday, July 7, 2026. The last 16 hours brought a surge of capital into frontier tech: AI infrastructure, deep energy, and defense systems. Investors funneled mega-rounds into enterprise AI and chip startups (for example, Palo Alto’... |
| 08.07.2026 | Beeline Medicines Inks Upsized Series A of $426.3M |
BOSTON, MA, Beeline Medicines Corporation, a clinical-stage biotechnology company, announced the closing of a $126.3 million Series A extension.
>> Click here for more funding data on Beeline Medicines
>> To export Beeline Medi... |
| 06.07.2026 | Beeline Medicines Raises $126.3M in Series A Extension Funding | Beeline Medicines Corporation, a Stamford, CT-based clinical-stage biotechnology company focused on developing and delivering precision therapies for people with autoimmune and inflammatory diseases, raised $126.3M in Series A extension fun... |
| 27.04.2026 | Beeline Medicines Ignites Precision Immunology with $300M Funding | Beeline Medicines secured $300 million in Series A funding, spearheaded by Bain Capital. This biotech now officially launches, poised to revolutionize treatment for autoimmune and inflammatory diseases. Its foundation rests on five clinical... |
| 22.04.2026 | Beeline Medicines: $300 Million Series A Launches Precision Immunology Biotech With Broad Pipeline | Beeline Medicines officially launched with $300 million in Series A financing led by Bain Capital, positioning the company to develop next-generation precision therapies for autoimmune and inflammatory diseases.
Originally formed in July 20... |
| 16.04.2026 | Beeline Medicines Raises $300M in Series A Financing | Beeline Medicines, a Stamford, Connecticut-based clinical-stage biotechnology company, raised $300m in Series A financing.
The round was led by Bain Capital.
The company intends to use the funds to advance its pipeline.
Beeline Medicines is... |
| - | Beeline Medicines | “https://beelinemedicines.com/wp-content/uploads/2026/04/beelinemedicines-website-header-reel-041326-v6_lwJkckeD.mp4https://beelinemedicines.com/wp-content/uploads/2026/04/beeline-webheadergrid-1920×1080-vertical_U4mo5aCr.mp4 Let’s get to w... |